Miltenyi Biomedicine is a biopharmaceutical company that develops innovative cell and gene therapies. We are committed to bring cancer treatments and regenerative therapies to patients with unmet medical needs worldwide. We work in partnership with physicians and other healthcare providers to expand access to new therapies. 
Our clinical research program includes: CAR T, CAR NK, our proprietary Adapter CAR™ and induced pluripotent stem cells (iPSC) technologies. 
For more information, please visit our website at www.miltenyibiomedicine.com.

Biotechnology

Clinical Trials

Medical Devices

Pharmaceutical

Miltenyi Biomedicine

Toon Overstijns

Michael Terhoeven

Dr. Sandra Karitzky

Peter Toth

Hans-Juergen Fuelle

Tomasz Skrzypczak

Hans - Jürgen Fülle

Andreas Woitossek

Anna Wijatyk

The Clinical Research and Development team at Miltenyi Biomedicine leads the design, execution, and oversight of clinical trials for our groundbreaking cell and gene therapies, including CAR T, CAR NK, Adapter CAR™, and iPSC technologies. The team ensures compliance with international regulatory standards, coordinates with medical professionals, and translates preclinical findings into clinical applications to advance innovative treatments for unmet medical needs.

Clinical Research and Development

Regulatory Affairs and Market Access

Leadership Team

Clinical Research and Development

About

Team members

Other teams at Miltenyi Biomedicine

Regulatory Affairs and Market Access

Leadership Team